Hepatitis/MASH

Revised plan incorporates lessons from the COVID-19 pandemic and recent advances in technology, aligning with the Department of Health and Human Services’ roadmap.

The B-Clear study investigated the efficacy and safety of 12- or 24-weeks treatment with bepirovirsen in individuals with chronic hepatitis B.

Participants who initiated treatment with Biktarvy demonstrated superior hepatitis B virus (HBV) DNA suppression and HBV e-antigen seroconversion.

Heavy alcohol intake and ALDH2 rs671 polymorphism are among many risk factors associated with increased risk of hepatocellular carcinoma and mortality in patients with hepatitis B virus-related cirrhosis.

A possibly life-threatening and transmissible liver disease has been affecting children in the US and the UK since 2021.

Elecsys HCV Duo allows independent and simultaneous determination of early-stage infection and those who are recovering or showing signs of a chronic problem.

Methotrexate is an immunosuppressive agent used to treat cancer, dermatology-, and rheumatology-related issues.

Hepatitis-associated emergency department visits and hospitalizations, liver transplantations, and adenovirus stool testing results in pediatric patients were not found to increase during the COVID-19 pandemic.

Findings from a study highlight the efficacy and safety of bulevirtide for the treatment of chronic hepatitis delta virus.

The coexistence of hepatitis B virus (HBV) surface antigens and antibodies against are an atypical serological profile for patients with chronic HBV infections.

The Advisory Committee on Immunization Practices and CDC have prioritized making HBV vaccination recommendations simpler to ease the vaccination process for immunizers and to decrease barriers.

Fresh organic strawberries sold at multiple major retailers linked to multistate hepatitis A outbreak.

Health systems should review HHS’ action plan and determine how to leverage cost savings to help eradicate HCV.

They play an indispensable role in the vaccination and management of complex regimens.

Investigators suggested a new test method for the infection with ESAT6/CFP10 and to monitor the disease development and treatment with Ag85B.

:Simeprevir (Olysio) is an NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen.

Many of patients with hepatitis that pharmacists encounter have viral hepatitis, which can be easily remembered as the ABCs of hepatitis.

Adenovirus has been noted in some patients throughout Europe, but not among all of them so investigators are considering other potential causes and contributing factors in the hepatitis outbreak.

Vosevi is a fixed-dose combination for the treatment of hepatitis C virus.

Vosevi is a fixed-dose combination product containing sofosbuvir, velpatasvir, and voxilaprevir for the re-treatment of adults with chronic hepatitis C.

The first cases were identified in October 2021 at a children’s hospital in Alabama that admitted 5 children with significant liver injury, including some with acute liver failure.

An earlier clinical trial found a higher number of acute myocardial infarction events in those administered HepB-CpG vaccine versus those administered the HepB-alum vaccine.

Getting an appointment with an infectious diseases specialist, particularly after giving birth and while managing a chronic disorder, such as substance use, is difficult, investigators say.

New CDC guidelines based on four decades of safety, immunogenicity, and efficacy data on the HBV vaccine, but with suboptimal coverage in the United States.